Company Description: Oniria Therapeutics, a Barcelona-based SME in precision oncology, aims to revolutionize cancer treatment by bringing to market the first-in-class drug ONR-001, designed for solid and liquid aggressive tumors unresponsive to current treatments, paving the way for novel therapeutic combinations or standalone treatments. From a broader perspective, the advantages of our proposed therapy lie in its precision, which increases the likelihood of achieving high efficacy rates while minimizing adverse effects. Moreover, due to its specific target, it also helps prevent cancer relapse and metastasis, thereby extending patients' life expectancy and improving the effectiveness of the Standard of Care (SoC) by reducing its required dosage. In parallel, Oniria Therapeutics is developing a highly sensitive biosensor (EpiGold-G) to detect epigenetic modifications of DNA from ultra-low amounts of biological material present in a liquid biopsy, which will work of a Companion Diagnostics test test to mitigate clinical trial risks, by selecting the patients that will benefit from the drug and validating therapeutic effects at the molecular level for each patient.